Alpha Cognition Inc
- ACOG
- NASDAQ
- Biotechnology
- Alzheimer's Treatment
- Neurodegenerative Diseases
$8.50
Today +3.79%Quote Oct 19, 2026, 08:00 PM UTC
−3.74%over the last month
Max drawdown −10.5%From 1-month high −7.1%3 months +7.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Alpha Cognition
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
71
Founded
2000
Market value
$185.1M
Quote Oct 19
Floor
$8.44
0.7% below price
Resistance
$8.66
1.9% above price
Price vs analyst targets
1 analyst
Lowest target
$12.00Highest target
$20.00
$12.00Highest target
$20.00
- Price $8.50
- Average target $17.25
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 103% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ACOGPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free